European in-house counsel at Novartis, DSM and other generics and originator manufacturers tell Managing IP about the prospects and problems of individual treatments, particularly as AI plays a bigger role in making them
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
Patrick assists with editorial agenda management, and regularly reports on patent-related issues, including FRAND, supplementary protection certificates and patent eligibility, as well as trade secrets. He also chairs industry events and produces conference newspapers.